Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
02:21pm, Tuesday, 29'th Jul 2025
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
07:00am, Tuesday, 29'th Jul 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
09:10am, Monday, 28'th Jul 2025
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., h
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
08:02am, Thursday, 24'th Jul 2025
LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sa
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:B
Bausch Health Appoints New Chief Accounting Officer
04:15pm, Thursday, 10'th Jul 2025
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vi
LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene an
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / B
Bausch Health to Announce Second Quarter 2025 Results on July 30
07:00am, Wednesday, 02'nd Jul 2025
LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to
Five Popular Stocks Insiders Have Been Aggressively Buying
09:10am, Tuesday, 24'th Jun 2025
We have to consider that insiders buying their stock wouldn't put up their own money unless they believed the move would be profitable.
Insiders Make Huge Buys in Gold Miners and More
08:45am, Thursday, 19'th Jun 2025
In the past week or so, a couple of gold-mining stocks attracted the attention of insider buyers.
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares
11:01am, Wednesday, 18'th Jun 2025
Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.
Repricing Potential Driven By Deleveraging
04:04am, Monday, 16'th Jun 2025
Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended d
